Image source: Getty Images
It was another busy week for Australia’s top brokers. This led to the release of a large number of broker notes.
Three ASX broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
IDP Education Ltd (ASX: IEL)
According to a note out of Goldman Sachs, its analysts have reiterated their buy and $29.65 price target on this language testing and student placement company’s shares. Goldman continues to forecast very strong earnings growth through to FY 2026 despite Canada-India tensions and changes to student visa regulations in Australia. It feels that if Indian students don’t go to Canada, they will end up in other IDP markets. It also suspects that the visa changes will not impact legitimate student placement providers like IDP. The IDP Education share price ended the week at $22.47.
A note out of Citi reveals that its analysts have retained their buy rating and $325.00 price target on this biotherapeutics giant’s shares. Citi has been looking at weight loss drug Ozempic’s potential expansion into treating chronic kidney disease. The broker estimates that CSL generates 7% of its revenue from nephrology. However, it doesn’t appear overly concerned at this point. Citi continues to forecast CSL Vifor revenue growth of 4.5% per annum through to FY 2028. The CSL share price was fetching $241.39 at Friday’s close.
Macquarie Group Ltd (ASX: MQG)
Analysts at UBS have retained their buy rating and $196.00 price target on this investment bank’s shares. The broker has been looking at Macquarie ahead of its results release in the coming weeks. Although it is expecting the bank to report a sharp decline in earnings, it doesn’t think this should stop investors from picking up shares today. Especially with the market already pricing it in. The Macquarie share price ended the week at $169.96.
